Screening Methods for Anti-Asthmatic Drugs

Screening Methods for Anti-Asthmatic Drugs

1. Definition, rationale & disease features modelled

• Anti-asthmatic drug screening = the structured pre-clinical evaluation of candidate bronchodilators and anti-inflammatory/anti-allergic agents in in vitro binding/cell assays, isolated airway-tissue preparations, and whole-animal models that reproduce one or more features of human asthma (SK Gupta Ch.44, pp.683–684).
• Asthma is the modelled disease: a complex inflammatory airway disorder defined by reversible airflow obstruction, airway inflammation, excess mucus, and bronchial hyperresponsiveness (BHR); the screening readouts (reduced FEV₁, increased airway resistance) mirror these clinical features (SK Gupta Ch.44, p.683).
• Two pharmacological targets are screened separately because asthma therapy has two arms (SK Gupta Ch.44, p.683):
  • Short-term relief / bronchodilation — β₂-adrenoceptor agonists (most widely used), methylxanthines (theophylline), antimuscarinics (ipratropium bromide). Screens use acute spasmogen-induced bronchoconstriction that the test drug must reverse or prevent.
  • Long-term control / anti-inflammatory — inhaled corticosteroids (budesonide) and inhibitors of mast-cell degranulation (cromolyn/sodium cromoglicate, nedocromil sodium). Screens use sensitisation–challenge (allergic) models with cellular-inflammation endpoints.
• Why animal models are needed: they let investigators probe underlying mechanisms of asthma/allergy and identify novel therapies in a predictable way; no single model is identical to human disease, so each model's value must be judged against its relevance to the human condition (SK Gupta Ch.44, pp.683–684; pp.693–694).
• Early- vs late-phase modelling: because all allergic diseases show an early-phase (immediate bronchoconstriction) and a late-phase (cellular infiltration, BHR, remodelling) response, validated screening batteries include models of both phases plus a model of increased airway responsiveness (SK Gupta Ch.44, p.693).
• Reference (standard) drugs anchor every assay — isoprenaline and aminophylline (relaxant standards in isolated organ work); atropine (vs ACh/methacholine spasm), aminophylline (vs bradykinin spasm), antihistamine e.g. tolpropamine/mepyramine (vs histamine spasm), imipramine (vs serotonin spasm); cromolyn/nedocromil for mast-cell-dependent endpoints (Vogel V1 Part IV, pp.936, 944; SK Gupta Ch.44, pp.687–691).

Tiered screening cascade (organising framework)

• The chapter structure of all three sources implies a tiered cascade, screening from cheap/high-throughput to expensive/disease-relevant (SK Gupta Ch.44, pp.684–692; Vogel V1 Part IV, pp.933–949):
  • Tier 1 — in vitro: receptor-binding affinity (H₁), cell-culture exposure systems (CULTEX/WST).
  • Tier 2 — isolated organ / ex vivo: guinea-pig lung strips, isolated tracheal chain, isolated perfused trachea, isolated perfused lung.
  • Tier 3 — in vivo acute: Konzett–Rössler bronchospasmolysis, histamine/serotonin aerosol asphyxia (preconvulsion time), pneumotachography/plethysmography.
  • Tier 4 — in vivo allergic (sensitisation–challenge): anaphylactic microshock, ovalbumin-sensitised airway inflammation, BAL eosinophilia, BHR.